The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models.
 
Jennifer Taylor Veneris
Employment - Abbott Laboratories (I); Takeda (I)
Stock and Other Ownership Interests - Abbvie (I)
 
Xiaonan Hou
No Relationships to Disclose
 
S. John Weroha
Research Funding - Genentech; KIYATEC; Novartis; Tesaro
Patents, Royalties, Other Intellectual Property - KIYATEC
 
Ethan P. Heinzen
No Relationships to Disclose
 
Matthew John Maurer
Consulting or Advisory Role - MorphoSys
Research Funding - Celgene (Inst); NanoString Technologies (Inst)
 
Ann L. Oberg
No Relationships to Disclose
 
Suzanne D. Conzen
Consulting or Advisory Role - Arno Therapeutics
Patents, Royalties, Other Intellectual Property - A GR antagonist methods patent owned by the University of Chicago that I am a co-Inventor on is licensed to Corcept Therapeutics
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Gini F. Fleming
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Corcept Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)